This study is for individuals ages 18-65, who have active opioid use disorder and are interested in receiving long-acting injectable naltrexone injections (Vivitrol®).
This study will test if adding an additional medication called buprenorphine-naloxone will help people stay on long-acting naltrexone injections.
Participants starting treatment with Vivitrol® will be randomly assigned to receive additional buprenorphine or placebo tablets. Random means by chance, it’s like flipping a coin.
You will be monitored over 24 weeks (6 months).
This includes:
- Receiving injectable naltrexone (Vivitrol®) every 4 weeks. Vivitrol can be provided at no cost through the study for qualifying participants.
- Weekly sessions with a medical clinician and research (medical check-in, vital sign check, and urine drug screening). Transportation can be provided for participants via Uber Health.
Compensation will be provided after each study visit. The maximum amount earned over the 24 weeks for attending all study visits will be $770.
Please call or text 240-739-0626 for more information.